Literature DB >> 24101836

A Turkish family with Sjögren-Larsson syndrome caused by a novel ALDH3A2 mutation.

Faruk Incecık1, Ozlem M Herguner, Wiliam B Rizzo, Sakir Altunbasak.   

Abstract

Sjögren-Larsson syndrome (SLS) is an inherited neurocutaneous disorder caused by mutations in the aldehyde dehydrogenase family 3 member A2 (ALDH3A2) gene that encodes fatty aldehyde dehydrogenase. Affected patients display ichthyosis, mental retardation, and spastic diplegia. More than 70 mutations in ALDH3A2 have been discovered in SLS patients. We diagnosed two brothers age of 12 and 20 years with characteristic features of this rare syndrome. Magnetic resonance imaging showed demyelinating disease in both of them. We described a novel homozygous, c. 835 T > A (p.Y279N) mutation in exon 6 in two patients.

Entities:  

Keywords:  Ichthyosis; mental retardation; mutation; spastic diplegia

Year:  2013        PMID: 24101836      PMCID: PMC3788300          DOI: 10.4103/0972-2327.116927

Source DB:  PubMed          Journal:  Ann Indian Acad Neurol        ISSN: 0972-2327            Impact factor:   1.383


Introduction

Sjögren-Larsson syndrome (SLS) is a rare autosomal recessive disorder characterized by mental retardation, spastic diplegia or tetraplegia, and congenital ichthyosis. Less common features are retinal changes, short stature, kyphoscoliosis, pre-term birth, photophobia, reduction of visual acuity, seizures, and delayed speech.[1] It occurs in all races and its prevalence has been estimated as 0.4 per 100,000 or lower.[2] SLS is caused by mutation in the gene ALDH3A2 for the microsomal enzyme fatty aldehyde dehydrogenase (FALDH) on chromosome 17p11.2.[3] In the present study, we report homozygous novel mutations in ALDH3A2 in a Turkish family with SLS.

Case Reports

Case 1

Index patient was a 12-year-old boy who was admitted to the hospital for generalized dryness of skin and developmental delay. He was moderate mentally retarded and unable to walk. He was the second child of healthy consanguineous parents. He had delivered at pre-term (32 weeks of gestation) by normal vaginal delivery. There was no history of maternal diabetes or exposure to any teratogenic agent during the pregnancy. Birth weight, length, and head circumference measurements were unknown. He had first evaluated for delayed walking at 2.5 years of age and cerebral magnetic resonance imaging (MRI) had detected symmetrical white matter lesions. The diagnosis was spastic diplegic type of cerebral palsy, which resulted from premature birth and MRI findings. He had global developmental delay and he had generalized seizures since 7 years of age that had been controlled with valproic acid treatment. Physical examination showed generalized dryness of skin most predominant around the umbilicus and on the bilateral lower limbs [Figure 1]. The face, palms, and soles were affected, but the nails and teeth appeared normal. Skeletal abnormalities (e.g., short stature, kyphoscoliosis) were not observed. Neurological examination revealed moderate mental retardation, and spasticity. The deep tendon reflexes were brisk in the lower limbs and he had muscle weakness of grade 3/5 in both lower limbs and could not walk. Ophthalmologic examination was normal.
Figure 1

Ichthyosis in case 1

Ichthyosis in case 1 In laboratory, metabolic investigations including, serum lactate, pyruvate, tandem mass spectrometry, urine organic acids, and phytanic acid revealed were normal. His electroencephalogram (EEG) showed symmetrical slow background activity without other abnormalities. MRI of the brain showed diffuse and symmetrical high-signal intensity in bilateral deep periventricular white matter in the corona radiata [Figure 2].
Figure 2

Axial magnetic resonance imaging showing bilateral symmetrical hyper-intense lesions corona radiata

Axial magnetic resonance imaging showing bilateral symmetrical hyper-intense lesions corona radiata

Case 2

The patient was the brother of case 1. He had had severe ichthyosis on the entire body since birth, especially, prominent on the bilateral lower limbs. He showed mental retardation and spastic tetraplegia. He was delivered at full-term by normal vaginal delivery. Birth weight, length, and head circumference measurements were unknown. At the age of four, he evaluated for delayed walking. MRI of the brain had performed and revealed periventricular white matter abnormalities. The diagnosis was cerebral palsy due to clinical and MRI findings. He had begun tip-toe walking at the age of 5 years, and his gait was spastic and walking in smooth floor. Cutaneous examination revealed generalized ichthyosis on the entire body. The face, palms, and soles were affected, but the nails and teeth were normal. There were no skeletal abnormalities. In neurological examination, he had mental retardation and spasticity and his gait was spastic with brisk deep tendon reflexes in the lower limbs. The patients had grade 4/5 power in both lower limbs. Ophthalmologic examination revealed bilateral glistening dots on the macular region of the retina. Brain MRI showed demyelination in the deep periventricular white matter [Figure 3].
Figure 3

Axial magnetic resonance imaging showing bilateral symmetrical hyper-intense lesions in periventricular white

Axial magnetic resonance imaging showing bilateral symmetrical hyper-intense lesions in periventricular white The younger brother had severe spasticity and the cutaneous findings, also could not walking. Clinical features of the patients were shown in [Table 1].
Table 1

Clinical features of the patients

Clinical features of the patients Clinical findings suggested SLS, and the mutation analysis of the FALDH gene revealed a homozygous novel mutation c. 835 T > A (p.Y279N) in exon 6.

Discussion

SLS is a recessively inherited disease with congenital ichthyosis, mental retardation, and spastic diplegia or tetraplegia, caused by a FALDH deficiency. FALDH catalyzes the oxidation of long chain aldehyde to fatty acids. Due to deficiency of this enzyme, there is an accumulation of aldehyde-modified lipids or fatty alcohol in the skin and in the myelin.[1] Over 200 cases have been reported in world-wide. There are more than 70 mutations described.[3] There may be also epilepsy, speech defects, dental, dermatological, skeletal, and retinal changes in patients with SLS.[4] The cutaneous symptoms are in form of icthyosis, which is a generalized hyperkeratosis of the trunk, joints, and the dorsal aspects of the hands and the feet. Patients usually have a dry and mildly erythrodermic skin at birth with worsening of cutaneous symptoms during the 1st year of life. Pruritus is a prominent feature that is not found in other types of ichthyotic skin disorders.[14] The occurrence of glistening dots on fundus examination strongly suggests SLS. Other ophthalmologic abnormalities are photophobia, macular dystrophy, and decreased visual acuity. These features are seen in one-third of cases.[15] The elder brother had photophobia, and glistening dots. Ophthalmologic examination was normal in younger brother. The neurologic symptoms develop later in the 1st or 2nd year of life. Spasticity impedes motor development and prevents many patients from walking. Mental retardation ranges from mild to profound.[26] Most cases with SLS have learning disability and speech disorders, as in our cases. Mutation analysis of the ALDH3A2 gene is a highly sensitive method of confirming the diagnosis of SLS.[7] It does not require a skin biopsy or FALDH enzymatic assays. Davis et al.[8] reported the first genetically confirmed cases of SLS. These 2 apparently unrelated patients carried the same novel ALDH3A2 mutation, but exhibited significant. More than 70 mutations are described, and these mutations are different in rich. Yis et al.[9] reported three Turkish SLS patients with ichthyosis, developmental delay, spastic diplegia, and brain white matter disease. They identified c. 380 G > C mutation in exon 8 in two patients, and c. 228 G > A mutation in exon 5 in one patient. We detected a novel mutation (c. 835 T > A) in exon 6 in our patient. Clinical findings may be variable among siblings. Our patients had the classical triad of the disease, but the younger patient had severe neurological features, and cutaneous findings. The elder patient had photophobia, and glistening dots in ophthalmologic examination. The hallmark of SLS is demyelination of the cerebral white matter and of the corticospinal and vestibulospinal tracts. MRI reveals abnormal high-signal intensity in the periventricular white matter of the frontal lobes and at the level of the centrum semiovale and corpus callosum.[410] We described high-signal intensity in the periventricular white matter in elder brother, and high-signal intensity in the corona radiata in younger brother. In this report, we reported two brothers with SLS. Treatment of SLS is predominantly symptomatic because effective casual therapy strategies are not available to date; however, gene therapy studies may be successful in the future.
  10 in total

Review 1.  Sjogren-Larsson syndrome.

Authors:  Lívia Almeida Dutra; Pedro Braga-Neto; José Luiz Pedroso; Orlando Graziani Povoas Barsottini
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

2.  Sjögren-larsson syndrome.

Authors:  María R Sanabria; Rosa M Coco
Journal:  Ophthalmology       Date:  2011-10       Impact factor: 12.079

Review 3.  Sjögren-Larsson syndrome.

Authors:  Neil Gordon
Journal:  Dev Med Child Neurol       Date:  2007-02       Impact factor: 5.449

4.  Sjogren-Larsson syndrome: report of two cases.

Authors:  M Uppal; C R Srinivas; K T Thowfeeq
Journal:  Indian J Dermatol Venereol Leprol       Date:  2004 Mar-Apr       Impact factor: 2.545

Review 5.  Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjögren-Larsson syndrome.

Authors:  M A Willemsen; L IJlst; P M Steijlen; J J Rotteveel; J G de Jong; P H van Domburg; E Mayatepek; F J Gabreëls; R J Wanders
Journal:  Brain       Date:  2001-07       Impact factor: 13.501

6.  Sjögren-Larsson syndrome: report of monozygote twins and a case with a novel mutation.

Authors:  Uluç Yiş; Allesandro Terrinoni
Journal:  Turk J Pediatr       Date:  2012 Jan-Feb       Impact factor: 0.552

Review 7.  Sjögren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency.

Authors:  William B Rizzo
Journal:  Mol Genet Metab       Date:  2006-09-22       Impact factor: 4.797

Review 8.  Sjögren-Larsson syndrome: diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (ALDH3A2).

Authors:  William B Rizzo; Gael Carney
Journal:  Hum Mutat       Date:  2005-07       Impact factor: 4.878

9.  Novel mutation in Sjogren-Larsson syndrome is associated with divergent neurologic phenotypes.

Authors:  Kathleen Davis; Kenton R Holden; Dana S'Aulis; Claudia Amador; M Gisele Matheus; William B Rizzo
Journal:  J Child Neurol       Date:  2012-10-03       Impact factor: 1.987

10.  MR imaging and proton MR spectroscopic studies in Sjögren-Larsson syndrome: characterization of the leukoencephalopathy.

Authors:  Michèl A A P Willemsen; Marinette Van Der Graaf; Marjo S Van Der Knaap; Arend Heerschap; Peter H M F Van Domburg; Fons J M Gabreëls; Jan J Rotteveel
Journal:  AJNR Am J Neuroradiol       Date:  2004-04       Impact factor: 3.825

  10 in total
  3 in total

1.  A gatekeeper helix determines the substrate specificity of Sjögren-Larsson Syndrome enzyme fatty aldehyde dehydrogenase.

Authors:  Markus A Keller; Ulrich Zander; Julian E Fuchs; Christoph Kreutz; Katrin Watschinger; Thomas Mueller; Georg Golderer; Klaus R Liedl; Markus Ralser; Bernhard Kräutler; Ernst R Werner; Jose A Marquez
Journal:  Nat Commun       Date:  2014-07-22       Impact factor: 14.919

2.  Genotype and phenotype variability in Sjögren-Larsson syndrome.

Authors:  Maximilian Weustenfeld; Reiner Eidelpes; Matthias Schmuth; William B Rizzo; Johannes Zschocke; Markus A Keller
Journal:  Hum Mutat       Date:  2018-11-26       Impact factor: 4.878

3.  The first central precocious puberty proteomic profiles revealed multiple metabolic networks and novel key disease-associated proteins.

Authors:  Chunlin Wang; Qingqing Chen; Ke Yuan; Minfei He; Jianfang Zhu; Yanlan Fang; Jianhong Hu; Qingfeng Yan
Journal:  Aging (Albany NY)       Date:  2021-11-08       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.